F Douglas Ivey
Wenham, MA (USA)
Role(s):
Founder/Owner/Principal
Fission Pharmaceuticals
Find More Startups
Startup
Location:
Wenham
Industry:
Pharmaceuticals
Year Founded:
2007
Number Employees:
1-10 people
Description:
Compounds that inhibit PDE4 family proteins are sought to treat: depression, anxiety, Alzheimer’s disease, schizophrenia, psychosis, asthma, chronic obstructive pulmonary disease, rhinitis, psoriasis, memory loss, chronic lymphocytic leukemia, multiple sclerosis, rheumatoid arthritis, osteoporosis, cystic fibrosis, pain, and ulcerative colitis. Other studies show that PDE4 inhibitors block HIV replication. Yet, 26 years after the identification of rolipram as the first effective PDE4 inhibitor with anti-inflammatory and central nervous system effects, no PDE4 inhibitor has received FDA approval. This is due to the fact that this family of proteins is encoded by four different genes, and the inhibition of proteins produced by the PDE4D gene causes emetic (vomiting) and arrhythmia side-effects.
Our goal is to develop the first-to-market PDE4-inhibiting drugs for the treatment of inflammatory and neurological diseases by developing drugs that inhibit PDE4A and PDE4B, but not PDE4D enzymes.
Founder/Owner/Principal
Fission Pharmaceuticals
Find More Service Providers
Service Provider
Location:
Wenham
Description:
Our goal is to develop preclinical compounds that can be licensed to pharmaceutical companies interested in developing a new pipeline in the area of PDE4, PDE7, and PDE4/7 inhibitors and activators. We are also open to screening partnerships to initiate drug discovery programs for inhibitors of cAMP-specific, cGMP-specific, or dual-specificity PDEs among the nine other PDE families.
Services Provided:
- Outsourcing